Short Interest in Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY) Rises By 250.0%

Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY) was the target of a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 2,800 shares, a growth of 250.0% from the February 28th total of 800 shares. Based on an average trading volume of 531,600 shares, the days-to-cover ratio is presently 0.0 days. Approximately 0.0% of the shares of the stock are sold short.

Daiichi Sankyo Stock Performance

Shares of DSNKY opened at $24.49 on Friday. Daiichi Sankyo has a 12-month low of $22.47 and a 12-month high of $42.48. The company has a current ratio of 2.77, a quick ratio of 2.11 and a debt-to-equity ratio of 0.06. The company has a market cap of $46.73 billion and a PE ratio of 28.47. The stock has a 50-day moving average price of $24.92 and a 200-day moving average price of $28.89.

Daiichi Sankyo (OTCMKTS:DSNKY) last released its quarterly earnings results on Friday, January 31st. The company reported $0.22 EPS for the quarter. Daiichi Sankyo had a net margin of 13.62% and a return on equity of 14.53%. As a group, equities analysts forecast that Daiichi Sankyo will post 0.73 earnings per share for the current fiscal year.

About Daiichi Sankyo

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia.